New Zealand approves funding of sildenafil for Raynaud's phenomenon and bosentan for children with PAH
New Zealand’s Pharmaceutical Management Agency PHARMAC has approved proposals for funding Pfizer’s (NYSE: PFE) sildenafil (trade name Revatio for Raynaud’s and PAH and the active ingredient of erectile dysfunction drug Viagra) for Raynaud’s phenomenon from March 1, 2013 and bosentan, Swiss biotech firm Actelion’s (SIX: ATLN) Tracleer, as a first-line treatment option for children with idiopathic pulmonary arterial hypertension (PAH) or pulmonary hypertension secondary to congenital heart disease from 1 February 2013.
Sildenafil for Raynaud’s phenomenon
From March 1, sildenafil will be subject to the following Special Authority restrictions:
Initial application – (Raynaud’s phenomenon) from any relevant practitioner. Approvals valid without further renewal unless notified for patients meeting the following criteria:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze